Progen Announces PI-88 Phase 2 Lung Canc... ( BRISBANE Sept. 24 /- Progen Pharm...)

Progen Announces PI-88 Phase 2 Lung Cancer Results

Date:9/24/2007

BRISBANE, Sept. 24 /PRNewswire-FirstCall/ -- Progen Pharmaceuticals Limited (ASX: PGL; Nasdaq: PGLA) today announced that the Phase 2 trial administering 250mg of PI-88 in combination with the chemotherapeutic agent docetaxel to patients with advanced non small cell lung cancer did not meet its primary endpoint of significantly improving the progression-free rate at six months compared to docetaxel alone. The trial also did not meet its secondary endpoints of improvement in time to progression, response rate, overall survival and quality of life measures.

The overall data from this trial suggests that no further investigation of PI-88 in combination with docetaxel in patients with non small cell lung cancer that have failed platinum based first line therapies is warranted. However, nine patients in the study switched to PI-88 after experiencing toxicity or disease progression with docetaxel monotherapy. The data for this patient group suggests a potential survival benefit that Progen intends to investigate further with, amongst others, the clinicians involved in this study.

"We are disappointed, first and foremost, for the patients with non small cell lung cancer that have disease progression following platinum based chemotherapy as treatment options are limited," said Justus Homburg, Progen's Chief Executive Officer. "The outcome of this study has no impact on our Phase 3 registration strategy for patients with post-resection liver cancer which we announced today has been granted fast-track status designation by the U.S. FDA."

"It is quite common for new drugs to show benefit in one patient group but limited benefit in another. To date, PI-88 has shown evidence of benefit in patients with melanoma, multiple myeloma and post-resection liver cancer. In particular, PI-88 may be more active for tumors that are at an earlier disease stage, such as has been demonstrated in the PI-88 Phase 2 primary liver cancer trial" added Homburg. "In that tria
'/>"/>

SOURCE Progen Pharmaceuticals Limited
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Progenics and Wyeth Announce Positive Results from Three-Month Clinical-Extension Study of Subcutaneous Methylnaltrexone for the Treatment of Opioid-Induced Constipation in Patients with Advanced Illness
2. Progenics Announces Positive Results in Clinical Trial of Novel HIV Therapy
3. Progens Phase 2 Liver Cancer Trial Exceeds Efficacy Objective
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Sygnis Pharma AG announces date for presentation of clinical results
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone

Post Your Comments:

(Date:12/2/2009)... ALTO, Calif., Dec. 2 Va...mber 25, 2009, Varian, Inc. filed with the U.S. Se... on Form 10-K for the fiscal year ended October 2,... the Company,s web site at www.varianinc.com, by c... on "10-K" in the table shown. Stockholders may r...

(Date:12/2/2009)... NEW YORK, Dec. 2 Reportlinker.com...ailable in its catalogue: ,, Pharmaceutical C..., http://www.reportlinker.com/p0164248/Pharmace...ds.html ,, Global pharma industry faces nume...ion in generic markets, rising cost of new product...

(Date:12/2/2009)... PARK, Ill., Dec. 2 Abbo...ing a vast array of microorganisms has been named ...st magazine. A panel of expert judges evaluated ...rmine the year,s top innovations, with the winners...online at www.the-scien t ist.com/top10innovat...

Breaking Medicine Technology:Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 2 Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 3 Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 4 Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends 5 Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist 2 AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 1 AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 2 AcelRx Announces Successful Completion of End of Phase 2 Meeting on ARX 01 Sufentanil NanoTab PCA System for Post Operative Pain Management 60384 3 First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 1 First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 2 First Choice Health Services Inc Named to 2009 HomeCare Elite as a Top Home Health Care Provider 60382 3 Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 1 Stereotaxis Receives Notice of European Approval of an Additional Magnetic Irrigated Catheter 5865 2

[0] Varian, Inc. Announces Form 10-K Filing [0] Reportlinker Adds Pharmaceutical Contract Manufacturing - Global Market Trends [0] Abbott's Ibis Technology Named One of the Top Innovations for 2009 by The Scientist

...ences, Inc. (Nasdaq: RDEA ) today announced that ...ty of the Company,s non-nucleoside reverse,transcr...st the,human-immunodeficiency virus (HIV), the kno...nt strains., The data was presented at the 15th A... Infections (CROI) in Boston., The data showed th...

...and lipid effects between REYATAZ/ritonavir and...CETON, N.J., Feb. 6 Bristol-Myers Squibb,Company ...TLE study, in which,300 mg of once-daily REYATAZ(R...vir (REYATAZ/r) showed similar antiviral efficacy ...mg (lopinavir/r) in previously untreated,adult HIV...

Other Medicine Technology:Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 2 Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus 3 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 2 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 3 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 4 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 5 CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients 6

Ardea Biosciences Presents Preclinical Data Demonstrating Favorable Resistance Profiles for Non-Nucleoside Reverse Transcriptase Inhibitors for the Treatment of Human Immunodeficiency Virus CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients

(Date:12/2/2009)...c. 2 Reportlinker.com announces th...s catalogue: ,, Point of Care Diagnostics ,...Care-Diagnostics.html ,, Provides a complete r...nostics industry ,, Includes market forecasts t... ,, Covers federal regulation of POC testing ,...

(Date:12/2/2009)...Dec. 2 The Washington Post reporte...ording to Coremetrics, a marketing optimization co...onday compared to Cyber Monday 2008. ,, Contras...pas who reported today "Cyber Monday website traff...9%" - said Tiffany Amorosino, COO of Bella Sante. ...

(Date:12/2/2009)...ave metabolic syndrome, study finds , , ...ne isn,t enough to keep overweight college footbal...condition that can lead to heart disease, a new st...Division I colleges and found that two-thirds were...e, a group of conditions that raise the risk for h...

(Date:12/2/2009)... 2 In the wake of the f...inated with a plastics chemical linked to birth de...tely to protect infants and mothers. ,, The Hou...ol A, or BPA, in food and beverage containers. The... Rep. Edward Markey of Massachusetts, would protec...

(Date:12/2/2009).... 2 Independence Blue Cross (IBC) ...ith Lincoln Financial Group. IBC will be the prima...10,000 Lincoln Financial Group employees, retirees...oln plan offerings will include the PPO option and...I speak for all of us at Independence Blue Cross w...

[0] Reportlinker Adds Point of Care Diagnostics [0] The Washington Post Reported That Cyber Monday Website Traffic Rises 8%. Boston's Bella Sante Day Spas Cyber Monday Website Traffic Rises 76%.[0] Oversized College Football Players May Face Heart Risks [0] Pre-Polluted Babies: Congress Must Act to Protect Infants, Moms from Toxic Plastics Chemical BPA [0] Independence Blue Cross Secures All-Blue Contract with Lincoln Financial Group

...at the cox-2 inhibitor celecoxib, a common pain re...k of the most common cause of brain damage in pre...p blood vessels in a part of the brain that in pre...lastingly affected by cerebral palsy, mental retar...

...e risk of a type of kidney malignancy called renal...hers at Brigham and Women's Hospital in Boston fou...alcoholic beverage a day were about 30 percent les...nd other researchers reviewed data from 12 studies...

...s generally suffer in silence, cough up more money...th mixed results. And here comes the news tha...ring warranty on its workmanship, charging a flat ...nd the insurer another bill. Well the Geisin...

... a health authority in St. John's, Canada, has apo...tests that may have affected the care of hundreds...the Eastern Health Regional Authority agreed that ... that we didn't simply refer to it earlier,' Tille...

...of Cincinnati have developed a model that could im... helping physicians combine current clot-busting ...othermia. It is already known that lowerin...pproved stroke medication is an enzyme called tiss...

...s of the four sick public sector pharmaceutical an...overnments , the railways and the armed forces hav...hem profit making units. According to the ... Hindustan Organic Chemicals Limited have been rev...

Other Medicine News:Health News:Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies 2 Health News:Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies 3 Health News:US Hospital Group Offers Warranty on Surgeries 2 Health News:US Hospital Group Offers Warranty on Surgeries 3 Health News:Faulty Hormone Tests Compromised Healthcare Of Breast Cancer Patients 2 Health News:Researchers Develop Model That Aids in Treating Stroke Patients 2 Health News:Government Hospitals to the Rescue of Loss-making Pharma Companies 2

Common Pain Killer may Reduce the Risk of Brain Damage in Premature Babies Moderate Drinking may Lower Risk of Kidney Cancer US Hospital Group Offers Warranty on Surgeries Faulty Hormone Tests Compromised Healthcare Of Breast Cancer Patients Researchers Develop Model That Aids in Treating Stroke Patients Government Hospitals to the Rescue of Loss-making Pharma Companies

...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...

Medicine Products:

Allergens, Food, IgG Panel 18 Allergens, Food, Cereal Profile Allergen, Weed, Sheep Sorrel Allergen, Weed, Western Ragweed

Progen Announces PI-88 Phase 2 Lung Canc...( BRISBANE Sept. 24 /- Progen Pharm...),Health